KalVista Pharmaceuticals, Inc. (KALV) DCF Valuation

Valoración de DCF de Kalvista Pharmaceuticals, Inc. (Kalv)

US | Healthcare | Biotechnology | NASDAQ
KalVista Pharmaceuticals, Inc. (KALV) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

KalVista Pharmaceuticals, Inc. (KALV) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Simplifique la valoración de Kalvista Pharmaceuticals, Inc. (Kalv) con esta calculadora DCF personalizable! Con el verdadero Kalvista Pharmaceuticals, Inc. (Kalv) Financials y las entradas de pronóstico ajustables, puede probar escenarios y descubrir Kalvista Pharmaceuticals, Inc. (Kalv) valor razonable en minutos.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue 12.7 12.7 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 -100 0 0 -25 -25 -25 -25 -25
EBITDA -40.0 -45.6 -81.6 -92.1 -134.3 .0 .0 .0 .0 .0
EBITDA, % -315.37 -359.28 100 100 100 20 20 20 20 20
Depreciation .5 .7 .7 .8 .8 .0 .0 .0 .0 .0
Depreciation, % 4.14 5.13 100 100 100 61.85 61.85 61.85 61.85 61.85
EBIT -40.5 -46.2 -82.3 -92.9 -135.1 .0 .0 .0 .0 .0
EBIT, % -319.51 -364.41 100 100 100 20 20 20 20 20
Total Cash 67.7 248.9 166.2 149.4 210.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 16.5 10.4 .0 16.6 10.9
Account Receivables, % 130.24 82.1 100 100 100
Inventories .0 .0 2.7 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 100 100 100 60 60 60 60 60
Accounts Payable 1.7 2.0 3.6 4.8 9.1 .0 .0 .0 .0 .0
Accounts Payable, % 13.22 15.61 100 100 100 65.77 65.77 65.77 65.77 65.77
Capital Expenditure -.2 -.1 -.9 -1.2 -.4 .0 .0 .0 .0 .0
Capital Expenditure, % -1.73 -0.64618 100 100 100 -0.47597 -0.47597 -0.47597 -0.47597 -0.47597
Tax Rate, % 6.26 6.26 6.26 6.26 6.26 6.26 6.26 6.26 6.26 6.26
EBITAT -40.4 -44.5 -68.5 -74.9 -126.6 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -54.9 -37.5 -59.3 -87.9 -116.3 1.8 .0 .0 .0 .0
WACC, % 8.66 8.66 8.64 8.64 8.65 8.65 8.65 8.65 8.65 8.65
PV UFCF
SUM PV UFCF 1.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 2
Net Debt -24
Equity Value 26
Diluted Shares Outstanding, MM 37
Equity Value Per Share 0.71

What You Will Get

  • Real KALV Financial Data: Pre-filled with KalVista Pharmaceuticals’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See KalVista Pharmaceuticals’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive KALV Data: Pre-filled with KalVista's historical performance metrics and future projections.
  • Fully Customizable Inputs: Tailor revenue growth, profit margins, discount rates, tax implications, and capital investment plans.
  • Dynamic Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your specified inputs.
  • Scenario Analysis: Develop various forecast scenarios to evaluate different valuation possibilities.
  • User-Friendly Interface: Intuitive, organized, and suitable for both industry professionals and newcomers.

How It Works

  • Step 1: Download the prebuilt Excel template with KalVista Pharmaceuticals' (KALV) data included.
  • Step 2: Explore the pre-filled sheets and understand the key metrics for KalVista Pharmaceuticals.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including KalVista Pharmaceuticals' intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose This Calculator for KalVista Pharmaceuticals, Inc. (KALV)?

  • Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for KalVista Pharmaceuticals.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios specific to (KALV).
  • Detailed Insights: Instantly calculates the intrinsic value and Net Present Value for KalVista Pharmaceuticals.
  • Preloaded Data: Historical and projected data provide a solid foundation for analysis.
  • Professional Quality: Perfect for financial analysts, investors, and consultants focusing on (KALV).

Who Should Use This Product?

  • Pharmaceutical Students: Understand drug development processes and apply them using real-world case studies.
  • Researchers: Integrate advanced models into your studies on drug efficacy and market analysis.
  • Investors: Evaluate your investment strategies and analyze valuation metrics for KalVista Pharmaceuticals, Inc. (KALV).
  • Market Analysts: Enhance your analysis with a tailored, user-friendly financial model specific to the biotech sector.
  • Healthcare Entrepreneurs: Discover how established pharmaceutical companies like KalVista are valued and assessed.

What the Template Contains

  • Pre-Filled DCF Model: KalVista Pharmaceuticals’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate KalVista Pharmaceuticals’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.